

Section: 6. Anti-infective medicines > 6.4. Antiviral medicines > 6.4.2. Antiretrovirals > 6.4.2.1. Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

EMLc

Codes ATC: J05AF02

<b>Indication</b>	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified    Code ICD11: <a href="#">1C62.Z</a>
<b>INN</b>	Didanosine
<b>Type de médicament</b>	Chemical agent
<b>Type de liste</b>	Liste de base (EML) (EMLc)
<b>Formulations</b>	Oral > Liquid: 100 mg buffered powder for oral solution ; 167 mg buffered powder for oral solution ; 250 mg buffered powder for oral solution Oral > Solid: 25 mg buffered chewable dispersible tablet ; 50 mg buffered chewable dispersible tablet ; 100 mg buffered chewable dispersible tablet ; 150 mg buffered chewable dispersible tablet ; 200 mg buffered chewable dispersible tablet ; 125 mg unbuffered enteric coated capsule ; 200 mg unbuffered enteric coated capsule ; 250 mg unbuffered enteric coated capsule ; 400 mg unbuffered enteric coated capsule
<b>Historique des statuts LME</b>	Ajouté pour la première fois en 2002 ( <a href="#">TRS 914</a> ) Modifié en 2007 ( <a href="#">TRS 950</a> ) Retiré en 2015 ( <a href="#">TRS 994</a> )
<b>Sexe</b>	Tous
<b>Âge</b>	Aussi recommandé pour les enfants
<b>Équivalence thérapeutique</b>	La recommandation concerne ce médicament spécifique
<b>Renseignements sur le brevet</b>	Patents have expired in most jurisdictions Lire la suite <a href="#">sur les brevets</a> . 
<b>Wikipédia</b>	<a href="#">Didanosine</a> 
<b>DrugBank</b>	<a href="#">Didanosine</a> 

### Résumé des preuves et recommandation du comité d'experts

Didanosine was recommended for deletion from the EML and EMLc as it was not longer aligned with dosing guidelines in the 2013 WHO Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection (1). References: Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2013. Available from: [http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727\\_eng.pdf](http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf).

